March 17, 2021
February 25, 2021
Retrotope Granted Rare Pediatric Disease Designation from FDA for Lead Development Candidate, RT001, in Two Life-Threatening Neurodegenerative Indications
February 11, 2021
Retrotope Appoints Rick E Winningham as Chairman of Board of Directors in Advance of Key Clinical Trial Data Readouts
November 5, 2020
Merck to Acquire VelosBio
October 16, 2020
Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial
September 16, 2020
selectION Secures $5M Promissory Note
July 20, 2020
Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
July 8, 2020
VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology
June 30, 2020
Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia
May 20, 2020